Characterizing and monitoring the heterogeneity of a biotherapeutic protein has continued to present technical and logistical challenges to the biopharmaceutical industry. Improvements to analytical technologies and informatics have made the process quicker and more automated, but overall laboratory workflows have continued to be laborious and require high skill to generate accurate and reproducible profiles. The Waters Biopharmaceutical Platform Solution analyzes biotherapeutics at multiple levels of structure: intact protein, peptide digest, and released glycan, which can be deployed in regulated and non-regulated environments. We will show how this solution supports laboratories in streamlining data acquisition, processing, reviewing and generating required reports while maintaining compliance.
|9:15am||Establishing Biosimilarity: Characterization and Comparability of Biosimilar and Innovator Biotherapeutics
Asish Chakraborty, Ph.D., Business Development Manager, Waters Corporation
|10:30am||Deploying a Fit for Purpose LCMS Platform for Regulated BioPharmaceutical Development and Quality Control
Min Du, Ph.D., Biopharmaceutical Business Development Manager, Waters Corporation
|11:30am||Hot Topics in Data Integrity
Heather Rennie, Americas Services Marketing Manager, Waters Corporation
|12:00pm||Lunch provided by Waters|
For additional information or questions, please contact Ann_Gray@waters.com.
Tuesday, October 17, 2017
Pennsylvania Regional Laboratory
5205 Militia Hill Road
Plymouth Meeting, PA 19462